Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

Dalesio, Otilia; Tinteren, Harm van; Clarke, Michael; Pető, Richárd; Schröder, Fritz H.; Dechering, I; Evans, Vaughan; Godwin, Jon; Blumenstein, Brent A.; Crawford,; Denis, L.; Hall, R. R.; Hill, Catherine; Iversen, Peter; Shipley, William U.; Soloway, Mark S.; Sylvester, R.; Pct., Collaborat

doi:10.1016/s0140-6736(00)02163-2

Cited by 691 publications

(34 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The concept of total androgen blockade has been a subject of great controversy [14,15] But the meta-analysis published by the Prostate Cancer Trialists' Collaborative Group in the Lancet in 2000 demonstrated that the use of anti-androgen in conjunction with LHRH agonist results in an approximately 3% improvement in overall survival [16].…”

Section: Discussionmentioning

confidence: 99%

Testicular Metastasis of Prostatic Adenocarcinoma after Ablatherm® Treatment

Gregorio¹,

Nollevaux²,

D’Hondt³

et al. 2017

Med Surg Urol

View full text Add to dashboard Cite

Testicular metastases are rare in prostatic adenocarcinomas. The discovery is often fortuitous, and they are diagnosed with a histological examination. Metastasis is often confused with a primitive testicular tumor. We describe an 86-year-old patient with metastatic prostate adenocarcinoma that affected the left testis. The metastasis was discovered after Ablatherm ® treatment. A prostatic origin must be suspected in a patient over 50 years old with testicular metastasis. This study highlights the importance of clinicopathological investigation and immunohistochemistry in determining the etiopathogenesis of testicular masses.

show abstract

Section: Discussionmentioning

confidence: 99%

Testicular Metastasis of Prostatic Adenocarcinoma after Ablatherm® Treatment

Gregorio¹,

Nollevaux²,

D’Hondt³

et al. 2017

Med Surg Urol

View full text Add to dashboard Cite

show abstract

“…First castration (Orchiectomy -estrogens) (Huggins & Hodges 1941) First pure anti-androgen (flutamide) (Neri et al 1967) Structure of GnRH (Amoss et al 1971, Schally et al 1971 Combined androgen blockade (CAB) First neoadjuvant CAB + surgery (Labrie et al 1993) First treatment of localized disease with CAB (Labrie et al 2002) First prostate cancer treated with abiraterone (Attard et al 2008) First prostate cancer treated with MDV-3100 (Tran et al 2009) 19401950196019701980Years 199020002020 First medical castration with a GnRH agonist (Labrie et al 1980) First treatment (advanced disease) with CAB First addition of antiandrogen in castrationresistant prostate cancer (Labrie et al 1988a,b) Figure 1 Landmarks in the development of androgen blockade in prostate cancer.…”

Section: Orchiectomy or Estrogensmentioning

confidence: 99%

GnRH agonists and the rapidly increasing use of combined androgen blockade in prostate cancer

Labrie¹

2014

Endocrine-Related Cancer

View full text Add to dashboard Cite

The discovery of medical castration with GnRH agonists in 1979 rapidly replaced surgical castration and high doses of estrogens for the treatment of prostate cancer. Soon afterwards, it was discovered that androgens were made locally in the prostate from the inactive precursor DHEA of adrenal origin, a mechanism called intracrinology. Taking into account these novel facts, combined androgen blockade (CAB) using a pure antiandrogen combined with castration in order to block the two sources of androgens was first published in 1982. CAB was the first treatment shown in randomized and placebo-controlled trials to prolong life in prostate cancer, even at the metastatic stage. Most importantly, the results recently obtained with the novel pure antiandrogen enzalutamide as well as with abiraterone, an inhibitor of 17a-hydroxylase in castration-resistant prostate cancer, has revitalized the CAB concept. The effects of CAB observed on survival of heavily pretreated patients further demonstrates the importance of the androgens made locally in the prostate and are a strong motivation to apply CAB to efficiently block all sources of androgens earlier at start of treatment and, even better, before metastasis occurs. The future of research in this field thus seems to be centered on the development of more potent blockers of androgens formation and action in order to obtain better results at the metastatic stage and, for the localized stage, reduce the duration of treatment required to achieve complete apoptosis and control of prostate cancer proliferation before it reaches the metastatic or noncurable stage.

show abstract

“…Consequently, many patients prefer medical castration [4]. The role of maximal androgen blockade (MAB), the addition of an antiandrogen to castration, in the setting of locally advanced disease is still being discussed [5, 6]. …”

Section: Treatment Options For Locally Advanced Prostate Cancermentioning

confidence: 99%

Treatment of Locally Advanced Prostate Cancer – A New Role for Antiandrogen Monotherapy?

Abrahamsson¹

2001

European Urology

View full text Add to dashboard Cite

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

Cited by 691 publications

References 30 publications

Testicular Metastasis of Prostatic Adenocarcinoma after Ablatherm® Treatment

Testicular Metastasis of Prostatic Adenocarcinoma after Ablatherm® Treatment

GnRH agonists and the rapidly increasing use of combined androgen blockade in prostate cancer

Treatment of Locally Advanced Prostate Cancer – A New Role for Antiandrogen Monotherapy?

Contact Info

Product

Resources

About

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

Cited by 691 publications

References 30 publications

Testicular Metastasis of Prostatic Adenocarcinoma after Ablatherm® Treatment

Testicular Metastasis of Prostatic Adenocarcinoma after Ablatherm® Treatment

GnRH agonists and the rapidly increasing use of combined androgen blockade in prostate cancer

Treatment of Locally Advanced Prostate Cancer &ndash; A New Role for Antiandrogen Monotherapy?

Contact Info

Product

Resources

About

Treatment of Locally Advanced Prostate Cancer – A New Role for Antiandrogen Monotherapy?